2026 - PFG - ECD Treatment Options in Histiocytic Neoplasms - Samuel B. Reynolds

In this educational presentation from the Erdheim-Chester Disease Global Alliance (ECDGA), Dr. Samuel Reynolds, hematologist-oncologist at Moffitt Cancer Center in Tampa, Florida, and lead ECD Care Center physician, provides an overview of current and emerging treatment options for Erdheim-Chester Disease (ECD) and related histiocytic neoplasms. Dr. Reynolds explains how he approaches ECD treatment decisions by first helping patients understand where the disease begins: in the bone marrow, where blood-forming stem and progenitor cells give rise to different types of blood and immune cells. He discusses how monocytes can become tissue-resident macrophages, why ECD can look different from patient to patient, and how organ involvement, symptoms, imaging, pathology, and molecular testing all help guide care. This presentation covers important topics including: • How ECD fits within the broader landscape of histiocytic neoplasms • Why ECD can vary widely from one patient to another • The role of imaging in understanding the full extent of disease • Why pathology, immunostaining, and genetic sequencing are important in diagnosis and treatment planning • How physicians may think about localized disease versus multisystem disease • Why organ-threatening or life-threatening symptoms can influence treatment decisions • The role of ECD Care Centers and multidisciplinary collaboration • How targetable mutations and fusions may guide therapy choices • Current treatment approaches, including targeted therapy and systemic therapy • Treatment options on the horizon, including newer targeted approaches and clinical trials Dr. Reynolds also discusses how mutations in the MAPK pathway, including BRAF and other genetic alterations, have expanded treatment possibilities for ECD and related disorders. He emphasizes that treatment decisions are often complex and individualized, especially when considering disease location, symptom burden, genomic findings, treatment access, side effects, and financial toxicity. This video is part of ECDGA’s mission to raise awareness, provide education and support, and encourage research related to Erdheim-Chester Disease and related histiocytic disorders. The Erdheim-Chester Disease Global Alliance is a 501(c)(3) nonprofit organization dedicated to awareness, support, education, and research for those affected by ECD. Learn more about ECDGA, educational resources, events, research updates, and support opportunities at: https://www.erdheim-chester.org/ Disclaimer: The Erdheim-Chester Disease Global Alliance (ECDGA) does not provide medical advice, diagnoses, or treatments. All content is for informational purposes only. Please consult with a healthcare provider for medical concerns.